EUVIMEDEUVIMED entdecken
Open Access

Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country

Abdalla Awidi iD, Marah Alzu'bi, Nada Odeh iD, Jawad Alrawabdeh iD, Muntaser Al Zyoud iD, Yazan Hamadneh, Hisham Bawa'neh iD, Ahmad Magableh, Alaa Alshorman, Feras Al-Fararjeh, Tariq Aladily, Amer M Zeidan iD

JCO Global Oncology · 2024-02 · (10)

DOI: 10.1200/go.23.00281 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Global Oncology, 2024-02. Verfasst von Abdalla Awidi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical School, University of Jordan, Amman, Jordan. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Myelodysplastic syndromes (MDS) include a heterogeneous group of clonal bone marrow disorders characterized by ineffective hematopoiesis. They manifest as dysplasia in bone marrow hemopoietic elements associated with peripheral cytopenias with variable risk of AML transformation. PATIENTS AND METHODS We analyzed retrospectively registry data collected prospectively from patients with primary MDS and patients with MDS/myeloproliferative neoplasm (MPN) in the Jordan University Hospital between January 2007 and September 2021. The registry captured epidemiologic information such as date of diagnosis, age, gender, date of AML transformation, cytogenetics, MDS subtype, risk group according to Revised International Prognostic Scoring System, and survival. The registry also captured baseline ferritin, B12, and lactate dehydrogenase levels. RESULTS A total of 112 patients with MDS and MDS/MPN were included in the registry. Median age at diagnosis was 59 years. The male-to-female ratio was about 1.2. In a multivariate cox regression model, baseline serum ferritin significantly affected survival as patients with levels exceeding 1,000 μg/L had a risk of death three times higher compared with those with

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteHumansMaleFemaleMiddle AgedRetrospective StudiesDeveloping CountriesFerritins

Substanzen

Ferritins

Autor:innen und Institutionen

  • Medical School, University of Jordan, Amman, Jordan.
  • Jordan University Hospital, Amman, Jordan.
  • Cell Therapy Center, University of Jordan, Amman, Jordan.
  • Al-Basheer Hospital, Ministry of Health, Amman, Jordan.
  • Yale Cancer Center and Smilow Cancer Hospital, Yale University School of Medicine, New Haven, CT.

ORCID-Profile: Abdalla Awidi, Nada Odeh, Jawad Alrawabdeh, Muntaser Al Zyoud, Hisham Bawa'neh, Amer M Zeidan

Förderung

  • NCATS NIH HHS

Zitieren

APA

Awidi, A., Alzu'bi, M., Odeh, N., Alrawabdeh, J., Al Zyoud, M., Hamadneh, Y., Bawa'neh, H., Magableh, A., Alshorman, A., Al-Fararjeh, F., Aladily, T., & Zeidan, A. M. (2024). Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country. JCO Global Oncology. https://doi.org/10.1200/go.23.00281

Vancouver

Awidi A, Alzu'bi M, Odeh N, Alrawabdeh J, Al Zyoud M, Hamadneh Y, et al. Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country. JCO Global Oncology. 2024. doi:10.1200/go.23.00281

BibTeX
@article{Awidi2024,
  author = {Awidi, Abdalla and Alzu'bi, Marah and Odeh, Nada and Alrawabdeh, Jawad and Al Zyoud, Muntaser and Hamadneh, Yazan and Bawa'neh, Hisham and Magableh, Ahmad and Alshorman, Alaa and Al-Fararjeh, Feras and Aladily, Tariq and Zeidan, Amer M},
  title = {Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country},
  journal = {JCO Global Oncology},
  year = {2024},
  number = {10},
  doi = {10.1200/go.23.00281}
}
Kostenlos starten →